HP
FOMX

Hound Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Hound Partners’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-194,913
Closed -$1.12M – 42
2018
Q3 		$1.12M Buy
+194,913
New +$1.12M 0.03% 26

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Hound Partners's FOMX Position: Q4 2018 in Review

Hound Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2018, closing a stake of 194,913 shares — an estimated $1.12M sold.

Hound Partners first reported a position in FOMX in Q3 2018 and held it in 1 quarter. The position peaked at $1.12M in Q3 2018. 66 funds tracked by Wall St. Rank hold FOMX as of Q4 2018.

  • Hound Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Hound Partners sold 194,913 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2018, an estimated $1.12M.
  • Hound Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2018 and held it in 1 quarter.
  • Hound Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.12M in Q3 2018.
  • 66 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2018.

Based on Hound Partners's 13F filing for Q4 2018, filed 14 Feb 2019.